Chen Lv
Research Subjects
Research Interests
Chen Lv has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Lintuo Huang
Department of Orthopedics The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China
4 shared publicationsLu Wang
The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China
4 shared publicationsWenjun Lin
The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China
4 shared publicationsZhengxiang Huang
Department of Orthopedics, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
4 shared publicationsShengwu Yang
The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China
3 shared publicationsXiongbai Zhu
Department of Orthopedics, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
3 shared publications
Latest Publications
- Open Access
- 31 May 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1415740
Novel targets and therapies of metformin in dementia: old drug, new insights
Dementia is a devastating disorder characterized by progressive and persistent cognitive decline, imposing a heavy public health burden on the individual and society. Despite numerous efforts by researchers in the field of dementia, pharmacological treatments are limited to relieving symptoms and fail to prevent disease progression. Therefore, studies exploring novel therapeutics or repurposing classical drugs indicated for other diseases are urgently needed. Metformin, a first-line antihyperglycemic drug used to treat type 2 diabetes, has been shown to be beneficial in neurodegenerative diseases including dementia. This review discusses and evaluates the neuroprotective role of metformin in dementia, from the perspective of basic and clinical studies. Mechanistically, metformin has been shown to improve insulin resistance, reduce neuronal apoptosis, and decrease oxidative stress and neuroinflammation in the brain. Collectively, the current data presented here support the future potential of metformin as a potential therapeutic strategy for dementia. This study also inspires a new field for future translational studies and clinical research to discover novel therapeutic targets for dementia.
- 31 May 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1415740
Open AccessNovel targets and therapies of metformin in dementia: old drug, new insights
Dementia is a devastating disorder characterized by progressive and persistent cognitive decline, imposing a heavy public health burden on the individual and society. Despite numerous efforts by researchers in the field of dementia, pharmacological treatments are limited to relieving symptoms and fail to prevent disease progression. Therefore, studies exploring novel therapeutics or repurposing classical drugs indicated for other diseases are urgently needed. Metformin, a first-line antihyperglycemic drug used to treat type 2 diabetes, has been shown to be beneficial in neurodegenerative diseases including dementia. This review discusses and evaluates the neuroprotective role of metformin in dementia, from the perspective of basic and clinical studies. Mechanistically, metformin has been shown to improve insulin resistance, reduce neuronal apoptosis, and decrease oxidative stress and neuroinflammation in the brain. Collectively, the current data presented here support the future potential of metformin as a potential therapeutic strategy for dementia. This study also inspires a new field for future translational studies and clinical research to discover novel therapeutic targets for dementia.
- 5 February 2023
- Published by Wiley in Cell Biology International
- Vol. 47 (5) , 954-968
BML‐111 inhibits osteoclast differentiation by suppressing the MAPK and NF‐κB pathways, alleviating deterioration of the knee joints in a CIA rat model
Irreversible destruction of joints is the hallmark of rheumatoid arthritis (RA). Osteoclasts are the only bone‐resorbing cells and play an important role in joint rebuilding. BML‐111 (5(S),6(R),7‐trihydroxyheptanoic acid methyl ester, C8H16O5) is a synthetic lipoxin A4 agonist with antioxidant and anti‐inflammatory properties. The present study aimed to investigate the effect of BML‐111 on osteoclasts in vivo and in vitro, to investigate its therapeutic effect on joint destruction in RA. Cell Counting Kit‐8 assay and flow cytometry were used to exclude cytotoxic effects of BML‐111 to bone marrow‐derived macrophages (BMMs). Then, osteoclasts were differentiated in vitro from BMMs by used macrophage colony‐stimulating factor and receptor activator of nuclear factor‐κB ligand, and osteoclasts were observed following tartrate‐resistant acid phosphatase staining with or without BML‐111 treatment. Meanwhile, absorption pit assay and immunofluorescence staining of the fibrous actin ring were used to observe osteoclast function. Moreover, we examined mitogen‐activated protein kinase (MAPK) and nuclear factor‐κB (NF‐κB) activation. We established collagen‐induced arthritis in a rat model and, after treatment with BML‐111, joint swelling was measured and the knee joints were processed for histology. We also examined serum and tissue for osteoclastogenesis‐related markers. BML‐111 inhibited osteoclast formation and differentiation in a time‐ and concentration‐dependent manner, and downregulated the expression levels of MAPK and NF‐κB in vitro. Meanwhile, BML‐111 effectively alleviated joint structural damage and inhibited osteoclast formation in vivo. BML‐111 inhibited osteoclast formation and differentiation in vitro and in vivo, and delayed the progression of joint destruction.
- 5 February 2023
- Published by Wiley in Cell Biology International
- Vol. 47 (5) , 954-968
BML‐111 inhibits osteoclast differentiation by suppressing the MAPK and NF‐κB pathways, alleviating deterioration of the knee joints in a CIA rat model
Irreversible destruction of joints is the hallmark of rheumatoid arthritis (RA). Osteoclasts are the only bone‐resorbing cells and play an important role in joint rebuilding. BML‐111 (5(S),6(R),7‐trihydroxyheptanoic acid methyl ester, C8H16O5) is a synthetic lipoxin A4 agonist with antioxidant and anti‐inflammatory properties. The present study aimed to investigate the effect of BML‐111 on osteoclasts in vivo and in vitro, to investigate its therapeutic effect on joint destruction in RA. Cell Counting Kit‐8 assay and flow cytometry were used to exclude cytotoxic effects of BML‐111 to bone marrow‐derived macrophages (BMMs). Then, osteoclasts were differentiated in vitro from BMMs by used macrophage colony‐stimulating factor and receptor activator of nuclear factor‐κB ligand, and osteoclasts were observed following tartrate‐resistant acid phosphatase staining with or without BML‐111 treatment. Meanwhile, absorption pit assay and immunofluorescence staining of the fibrous actin ring were used to observe osteoclast function. Moreover, we examined mitogen‐activated protein kinase (MAPK) and nuclear factor‐κB (NF‐κB) activation. We established collagen‐induced arthritis in a rat model and, after treatment with BML‐111, joint swelling was measured and the knee joints were processed for histology. We also examined serum and tissue for osteoclastogenesis‐related markers. BML‐111 inhibited osteoclast formation and differentiation in a time‐ and concentration‐dependent manner, and downregulated the expression levels of MAPK and NF‐κB in vitro. Meanwhile, BML‐111 effectively alleviated joint structural damage and inhibited osteoclast formation in vivo. BML‐111 inhibited osteoclast formation and differentiation in vitro and in vivo, and delayed the progression of joint destruction.
- 29 March 2022
- Published by Wiley in Cell Biology International
- Vol. 46 (5) , 829-839
Glucosamine suppresses oxidative stress and induces protective autophagy in osteoblasts by blocking the ROS/Akt/mTOR signaling pathway
Oxidative stress is the crucial pathogenic factor in osteoporosis. Cell autophagy, a major form of self‐digestion, plays critical functions in different forms of stress by devouring harmful cytosolic proteins or organelles for the renewal of organelles and to maintain cellular homeostasis. Glucosamine (GlcN) has been widely utilized in treatments for patients with osteoarthritis‐related joint pain. It has potential antioxidant effects and its pharmacological effect in osteoblasts remains unclear. The present study aimed to investigate whether autophagy participates in the protective effects of GlcN in osteoblasts under oxidative stress and the possible mechanism. First of all, MC3T3‐E1 cells were treated with hydrogen peroxide (H2O2) to induce oxidative stress, as assessed by viability assays, apoptosis, the intracellular reactive oxygen species production. GlcN was capable of inducing autophagy and protected osteoblasts from those cytotoxic effects. Moreover, it significantly attenuated H2O2‐induced oxidative stress as measured by malondialdehyde, glutathione, nitrite, and superoxide dismutase levels. Importantly, the autophagy level increased in osteoblasts treated with GlcN as represented by an increase in both Beclin1 expression and the LC3 II/I ratio. Immunofluorescence analysis of autophagosomes also confirmed the above results. In addition, GlcN decreased the mammalian target of rapamycin (mTOR) and protein kinase B (Akt). However, the Akt activator (SC79) suppressed the autophagy level induced by GlcN in osteoblasts. Consequently, the antioxidant effects of GlcN were mediated, at least in part, by enhancing autophagy through the Akt/mTOR pathway. These results suggested that GlcN might be a promising candidate for osteoporosis treatment.
- 29 March 2022
- Published by Wiley in Cell Biology International
- Vol. 46 (5) , 829-839
Glucosamine suppresses oxidative stress and induces protective autophagy in osteoblasts by blocking the ROS/Akt/mTOR signaling pathway
Oxidative stress is the crucial pathogenic factor in osteoporosis. Cell autophagy, a major form of self‐digestion, plays critical functions in different forms of stress by devouring harmful cytosolic proteins or organelles for the renewal of organelles and to maintain cellular homeostasis. Glucosamine (GlcN) has been widely utilized in treatments for patients with osteoarthritis‐related joint pain. It has potential antioxidant effects and its pharmacological effect in osteoblasts remains unclear. The present study aimed to investigate whether autophagy participates in the protective effects of GlcN in osteoblasts under oxidative stress and the possible mechanism. First of all, MC3T3‐E1 cells were treated with hydrogen peroxide (H2O2) to induce oxidative stress, as assessed by viability assays, apoptosis, the intracellular reactive oxygen species production. GlcN was capable of inducing autophagy and protected osteoblasts from those cytotoxic effects. Moreover, it significantly attenuated H2O2‐induced oxidative stress as measured by malondialdehyde, glutathione, nitrite, and superoxide dismutase levels. Importantly, the autophagy level increased in osteoblasts treated with GlcN as represented by an increase in both Beclin1 expression and the LC3 II/I ratio. Immunofluorescence analysis of autophagosomes also confirmed the above results. In addition, GlcN decreased the mammalian target of rapamycin (mTOR) and protein kinase B (Akt). However, the Akt activator (SC79) suppressed the autophagy level induced by GlcN in osteoblasts. Consequently, the antioxidant effects of GlcN were mediated, at least in part, by enhancing autophagy through the Akt/mTOR pathway. These results suggested that GlcN might be a promising candidate for osteoporosis treatment.
- 25 March 2021
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 33 (5) , 328-341
Knockdown of microRNA-203 reduces cisplatin chemo-sensitivity to osteosarcoma cell lines MG63 and U2OS in vitro by targeting RUNX2
Clinical studies have reported that miRNAs abnormal expression are associated with the generation of cisplatin-resistant to osteosarcoma. Our previous research found that miR-203 is downregulated in osteosarcoma cells and overexpressed miR-203 exerts antitumor properties on osteosarcoma cells. However, the role and mechanism of miR-203 in regulating the sensitivity of cisplatin in osteosarcoma cells remains unclear. This study aimed to investigate the effects of miR-203 in cisplatin therapy for osteosarcoma cells in vitro and determined the underlying mechanism. In this study, we found that miR-203 was significantly upregulated in osteosarcoma cells after exposure to cisplatin. miR-203 knockdown reduced the sensitivity of osteosarcoma cells to cisplatin by suppressing cell apoptosis, cell cycle arrest, and inducing invasion. Meanwhile, we found that miR-203 knockdown reduces the therapeutic sensitivity of osteosarcoma cells by upregulating RUNX2. Moreover, we found that RUNX2 silencing sensitizes osteosarcoma cells to chemotherapy treatment of cisplatin. In summary, our findings demonstrated that miR-203 knockdown reduces cisplatin chemo-sensitivity to osteosarcoma cells in vitro by targeting RUNX2, and speculated that miR-203 may be a target for drug resistance of osteosarcoma to cisplatin.
- 25 March 2021
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 33 (5) , 328-341
Knockdown of microRNA-203 reduces cisplatin chemo-sensitivity to osteosarcoma cell lines MG63 and U2OS in vitro by targeting RUNX2
Clinical studies have reported that miRNAs abnormal expression are associated with the generation of cisplatin-resistant to osteosarcoma. Our previous research found that miR-203 is downregulated in osteosarcoma cells and overexpressed miR-203 exerts antitumor properties on osteosarcoma cells. However, the role and mechanism of miR-203 in regulating the sensitivity of cisplatin in osteosarcoma cells remains unclear. This study aimed to investigate the effects of miR-203 in cisplatin therapy for osteosarcoma cells in vitro and determined the underlying mechanism. In this study, we found that miR-203 was significantly upregulated in osteosarcoma cells after exposure to cisplatin. miR-203 knockdown reduced the sensitivity of osteosarcoma cells to cisplatin by suppressing cell apoptosis, cell cycle arrest, and inducing invasion. Meanwhile, we found that miR-203 knockdown reduces the therapeutic sensitivity of osteosarcoma cells by upregulating RUNX2. Moreover, we found that RUNX2 silencing sensitizes osteosarcoma cells to chemotherapy treatment of cisplatin. In summary, our findings demonstrated that miR-203 knockdown reduces cisplatin chemo-sensitivity to osteosarcoma cells in vitro by targeting RUNX2, and speculated that miR-203 may be a target for drug resistance of osteosarcoma to cisplatin.
- 22 February 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (12) , 5833-5842
TSP1 is the essential domain of SEMA5A involved in pannus formation in rheumatoid arthritis
In this study, we explored the effect of semaphorin5A (SEMA5A) on RA pathogenesis and its specific TSP1 domain on pannus formation. The expression of SEMA5A was detected in the synovium, the fibroblast-like synoviocytes (FLSs) and the SF of RA patients and healthy controls (HCs) by real-time quantitative PCR (q-PCR), immunohistochemistry staining, western blot and ELISA. SEMA5A-mAb intervention was performed to appraise the severity of joints in the CIA model. Transcriptome sequencing and bioinformatics analysis in SEMA5A-transfected FLSs from HCs were performed to screen differentially expressed genes after SEMA5A overexpression. An MTT assay in RA-FLSs, a chicken embryo allantoic membrane experiment and a tube formation experiment were used to clarify the influence of SEMA5A on cell proliferation and angiogenesis. Furthermore, a rescue experiment verified the function of the TSP1 domain of SEMA5A in the progress of RA with Sema5a−/− CIA mice. The expression of SEMA5A increased in RA compared with that in HCs. Simultaneously, SEMA5A-mAbs significantly attenuated joint injury and the inflammatory response in CIA models. In addition, transcriptome sequencing and angiogenesis-related experiments verified the ability of SEMA5A to promote FLS proliferation and angiogenesis. Moreover, TSP1 was proved to be an essential domain in SEMA5A-induced angiogenesis in vitro. Additionally, rescue of TSP1-deleted SEMA5A failed to reduce the severity of arthritis in a CIA model constructed with Sema5a −/− mice. In summary, upregulation of SEMA5A was first confirmed in pathological lesions of RA patients. Furthermore, treatment with SEMA5A-mAbs attenuated the progress of RA in the CIA model. Moreover, TSP1 was indicated as the key domain of SEMA5A in the promotion of pannus formation in RA. Graphical Abstract
- 22 February 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (12) , 5833-5842
TSP1 is the essential domain of SEMA5A involved in pannus formation in rheumatoid arthritis
In this study, we explored the effect of semaphorin5A (SEMA5A) on RA pathogenesis and its specific TSP1 domain on pannus formation. The expression of SEMA5A was detected in the synovium, the fibroblast-like synoviocytes (FLSs) and the SF of RA patients and healthy controls (HCs) by real-time quantitative PCR (q-PCR), immunohistochemistry staining, western blot and ELISA. SEMA5A-mAb intervention was performed to appraise the severity of joints in the CIA model. Transcriptome sequencing and bioinformatics analysis in SEMA5A-transfected FLSs from HCs were performed to screen differentially expressed genes after SEMA5A overexpression. An MTT assay in RA-FLSs, a chicken embryo allantoic membrane experiment and a tube formation experiment were used to clarify the influence of SEMA5A on cell proliferation and angiogenesis. Furthermore, a rescue experiment verified the function of the TSP1 domain of SEMA5A in the progress of RA with Sema5a−/− CIA mice. The expression of SEMA5A increased in RA compared with that in HCs. Simultaneously, SEMA5A-mAbs significantly attenuated joint injury and the inflammatory response in CIA models. In addition, transcriptome sequencing and angiogenesis-related experiments verified the ability of SEMA5A to promote FLS proliferation and angiogenesis. Moreover, TSP1 was proved to be an essential domain in SEMA5A-induced angiogenesis in vitro. Additionally, rescue of TSP1-deleted SEMA5A failed to reduce the severity of arthritis in a CIA model constructed with Sema5a −/− mice. In summary, upregulation of SEMA5A was first confirmed in pathological lesions of RA patients. Furthermore, treatment with SEMA5A-mAbs attenuated the progress of RA in the CIA model. Moreover, TSP1 was indicated as the key domain of SEMA5A in the promotion of pannus formation in RA. Graphical Abstract
- 1 June 2020
- Published by Elsevier in Toxicology in Vitro
- Vol. 65, 104775
Piperlongumine induces apoptosis and G2/M phase arrest in human osteosarcoma cells by regulating ROS/PI3K/Akt pathway
- 1 June 2020
- Published by Elsevier in Toxicology in Vitro
- Vol. 65, 104775
Piperlongumine induces apoptosis and G2/M phase arrest in human osteosarcoma cells by regulating ROS/PI3K/Akt pathway
- Open Access
- 10 April 2019
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 54 (6) , 1969-1980
Salidroside suppresses the growth and invasion of human osteosarcoma cell lines MG63 and U2OS in vitro by inhibiting the JAK2/STAT3 signaling pathway
Previous research has reported that salidroside exerts antitumor properties on numerous types of tumor cells; however, its effect on osteosarcoma cells remains unknown. The present study aimed to investigate the effects of salidroside on the viability, apoptosis and invasion of osteosarcoma cells in vitro, and determine the underlying mechanism of action. The results of an MTT revealed that salidroside suppressed the viability of osteosarcoma cells (MG63 and U2OS cells) in a time‑ and concentration‑dependent manner. The results of cell morphological analysis (profile observations and Hoechst 33258 staining) and the detection of apoptosis by flow cytometry further indicated that the decrease in osteosarcoma cell viability induced by salidroside was associated with cell apoptosis. Western blot analysis not only confirmed these results but also suggested that salidroside induced the apoptosis of osteosarcoma cells by activating the caspase‑9‑dependent apoptotic pathway. In addition, we reported that salidroside induced G0/G1 phase arrest and suppressed the invasion of osteosarcoma cells, as measured by flow cytometric cell cycle analysis and a Transwell invasion assay, respectively. Western blot analysis confirmed the aforementioned results. Furthermore, our findings demonstrated that salidroside induced the apoptosis, G0/G1 phase arrest and suppressed the invasion of osteosarcoma cells by inhibiting the janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway, as determined by western blot analysis. In summary, the findings of the present study suggested that salidroside may inhibit the progression of osteosarcoma by suppressing the growth and invasion of osteosarcoma cells. Furthermore, the investigations into the underlying mechanism demonstrated that salidroside exerted notable antitumor activity in osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.
- 10 April 2019
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 54 (6) , 1969-1980
Open AccessSalidroside suppresses the growth and invasion of human osteosarcoma cell lines MG63 and U2OS in vitro by inhibiting the JAK2/STAT3 signaling pathway
Previous research has reported that salidroside exerts antitumor properties on numerous types of tumor cells; however, its effect on osteosarcoma cells remains unknown. The present study aimed to investigate the effects of salidroside on the viability, apoptosis and invasion of osteosarcoma cells in vitro, and determine the underlying mechanism of action. The results of an MTT revealed that salidroside suppressed the viability of osteosarcoma cells (MG63 and U2OS cells) in a time‑ and concentration‑dependent manner. The results of cell morphological analysis (profile observations and Hoechst 33258 staining) and the detection of apoptosis by flow cytometry further indicated that the decrease in osteosarcoma cell viability induced by salidroside was associated with cell apoptosis. Western blot analysis not only confirmed these results but also suggested that salidroside induced the apoptosis of osteosarcoma cells by activating the caspase‑9‑dependent apoptotic pathway. In addition, we reported that salidroside induced G0/G1 phase arrest and suppressed the invasion of osteosarcoma cells, as measured by flow cytometric cell cycle analysis and a Transwell invasion assay, respectively. Western blot analysis confirmed the aforementioned results. Furthermore, our findings demonstrated that salidroside induced the apoptosis, G0/G1 phase arrest and suppressed the invasion of osteosarcoma cells by inhibiting the janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway, as determined by western blot analysis. In summary, the findings of the present study suggested that salidroside may inhibit the progression of osteosarcoma by suppressing the growth and invasion of osteosarcoma cells. Furthermore, the investigations into the underlying mechanism demonstrated that salidroside exerted notable antitumor activity in osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.
- 1 July 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 91, 1075-1084
MicroRNA-203 inhibits proliferation and invasion, and promotes apoptosis of osteosarcoma cells by targeting Runt-related transcription factor 2
- 1 July 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 91, 1075-1084
MicroRNA-203 inhibits proliferation and invasion, and promotes apoptosis of osteosarcoma cells by targeting Runt-related transcription factor 2
- 1 May 2016
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 27, 154-160
Role and mechanism of microRNA-21 in H2O2-induced apoptosis in bone marrow mesenchymal stem cells
- 1 May 2016
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 27, 154-160
Role and mechanism of microRNA-21 in H2O2-induced apoptosis in bone marrow mesenchymal stem cells